IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11596609 B1

PDFFull Text
Date of Patent:
Mar. 07, 2023

Filed:

Sep. 07, 2022

Combinations of mrnas encoding immune modulating polypeptides and uses thereof

Applicant:

Modernatx, Inc., Cambridge, MA (US);

Inventors:

Joshua Frederick, Cambridge, MA (US);

Ailin Bai, Cambridge, MA (US);

Vladimir Presnyak, Cambridge, MA (US);

Stephen Hoge, Cambridge, MA (US);

Kerry Benenato, Cambridge, MA (US);

Iain McFadyen, Cambridge, MA (US);

Ellalahewage Sathyajith Kumarasinghe, Cambridge, MA (US);

Susannah Hewitt, Cambridge, MA (US);

Assignee:

ModernaTX, Inc., Cambridge, MA (US);

Attorneys:

Cooley LLP

Amy Mandragouras

Ariana D. Harris

Primary Examiner:

Scott Long

Int. Cl.
CPC ...
A61K 9/51 (2006.01); A61K 48/00 (2006.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 9/00 (2006.01); A61K 39/39 (2006.01); A61K 45/06 (2006.01); A61K 9/127 (2006.01); C07K 14/54 (2006.01); C07K 14/545 (2006.01); C07K 14/705 (2006.01); A61K 31/7088 (2006.01); A61K 31/7115 (2006.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01); B82Y 5/00 (2011.01); C12N 15/88 (2006.01);
U.S. Cl.
CPC ...
A61K 9/5123 (2013.01); A61K 9/00 (2013.01); A61K 9/0019 (2013.01); A61K 9/1272 (2013.01); A61K 9/5146 (2013.01); A61K 31/7088 (2013.01); A61K 31/7115 (2013.01); A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61K 38/20 (2013.01); A61K 38/2006 (2013.01); A61K 38/208 (2013.01); A61K 38/2086 (2013.01); A61K 39/39 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 48/00 (2013.01); A61K 48/005 (2013.01); A61P 35/00 (2018.01); C07K 14/54 (2013.01); C07K 14/545 (2013.01); C07K 14/5434 (2013.01); C07K 14/5443 (2013.01); C07K 14/5446 (2013.01); C07K 14/70575 (2013.01); A61K 2039/505 (2013.01); A61K 2039/51 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/585 (2013.01); B82Y 5/00 (2013.01); C07K 2319/00 (2013.01); C12N 15/88 (2013.01);
Abstract

The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

Find Patent Forward Citations

Loading…